Category: 8. Health

  • Woman with terminal cancer makes Ironman comeback

    Woman with terminal cancer makes Ironman comeback

    A woman with terminal cancer has completed an Ironman challenge a month after she was forced to stop the race due to intense pain.

    Hannah Corne, from Leeds, was taking part in Ironman Leeds on 27 July when she was forced to pull out halfway through the cycling section of the race.

    Advertisement

    This weekend, she completed the cycle ride and marathon at Roundhay Park, watched by friends and family.

    She said: “It feels amazing. Ironman was one of the best days of my life. It was such an incredible thing to be a part of and to be able to finish it today is the icing on the cake.”

    Ms Corne completed the remainder of the 56-mile (90km) cycle race on Saturday and then ran a marathon (26 miles or 42km) on Sunday.

    Fifteen months ago she was diagnosed with stage four ocular melanoma, a rare cancer that spread to her liver and was told she had 12 months to live.

    Hannah Corne was joined in the challenge by her friends and family [BBC]

    She said as long as her body continued to allow her she would carry on setting herself physical challenges.

    Advertisement

    “It’s to show that even when you’ve got a devastating diagnosis like stage four cancer you can still live well and enjoy life.”

    She thanked her friends and family for joining her on the route.

    She added: “It’s overwhelming. I didn’t think so many people would be out, but they have all come out in force with snacks and great times and chat. It’s brilliant.”

    Listen to highlights from West Yorkshire on BBC Sounds, catch up with the latest episode of Look North.

    Related stories

    Continue Reading

  • Not just waistline, your neck size could reveal hidden health risks to watchout for

    Not just waistline, your neck size could reveal hidden health risks to watchout for

    While most people monitor their weight or waistline, emerging research suggests that neck circumference may provide crucial insight into overall health. Studies indicate that a thicker neck could signal a higher risk of conditions such as heart disease, diabetes, and sleep disorders—even for individuals with a normal Body Mass Index (BMI).

    Why BMI Alone Isn’t Enough

    BMI has long been used to estimate body fat based on height and weight. However, it has notable limitations. Experts, including Dr. Ahmed Elbediwy and Dr. Nadine Wehida from Kingston University, point out in a piece written for The Conversation that BMI cannot distinguish between muscle and fat, nor can it indicate where fat is stored in the body. For example, a competitive bodybuilder may have a high BMI but is not obese. In such cases, neck circumference offers an additional perspective, revealing the presence of visceral fat stored in the upper body.
    This upper-body fat is particularly concerning because it is metabolically active. It releases fatty acids, hormones, and inflammatory substances into the bloodstream, which can disrupt normal bodily functions, increase chronic inflammation, and drive insulin resistance. Over time, this places strain on organs and raises the likelihood of serious complications.

    Links to Cardiovascular and Metabolic Health

    Research has consistently linked larger neck measurements to a higher risk of type 2 and gestational diabetes. Multiple studies, including reports cited by the New York Post, have also associated neck size with key cardiovascular risk factors, such as high blood pressure, low HDL (“good”) cholesterol, and elevated triglycerides.Additionally, larger neck circumference has been connected to atrial fibrillation, a condition that causes irregular heartbeat and increases the risk of stroke, blood clots, and heart failure. These findings persist even when adjusting for BMI, waist circumference, height, and weight, although the risk appears particularly pronounced in individuals with obesity.
    Beyond metabolic and cardiovascular concerns, a thicker neck has been linked to obstructive sleep apnea, a condition characterized by repeated breathing interruptions during sleep. This disorder can cause severe daytime fatigue and further strain the heart. Some studies have also found correlations with erectile dysfunction in men.

    Measuring Your Neck

    Experts advise that neck circumference should not replace routine health check-ups but can serve as a useful additional tool. Generally, a neck measurement above 17 inches (43 cm) in men or 15.5 inches (35.5 cm) in women is considered large. Measuring is straightforward: wrap a tape measure around the narrowest part of the neck, keeping it snug but not tight.

    Monitoring neck size can help individuals better understand their health risks and take preventive action through lifestyle changes such as cardiovascular exercise, weight training, improved sleep, and a balanced diet.

    Add as a Reliable and Trusted News Source

    Continue Reading

  • Hidden Rhythms Between Your Stomach And Brain Could Shape Your Mood : ScienceAlert

    Hidden Rhythms Between Your Stomach And Brain Could Shape Your Mood : ScienceAlert

    A new study has identified a link between mental health and the stomach, a region of the gut rarely covered in research on the complex interplay between the central nervous system and the digestive tract.

    Both the stomach and the brain have a constant pattern of electrical waves pulsing through them, on a low level, and it was found that the more in sync these two patterns are, the higher the chance of someone being in mental distress.

    The study was conducted by a team from Aarhus University in Denmark and the German Institute of Human Nutrition. The researchers hope that we might eventually be able to diagnose certain mental health issues more precisely, or earlier, via stomach signals.

    Related: An Extra Sense May Connect Gut Bacteria With Our Brain

    “Intuitively, we assume stronger body-brain communication is a sign of health,” says neuroscientist Micah Allen from Aarhus University.

    “But here, unusually strong stomach-brain coupling seems linked to greater psychological burden – perhaps a system under strain.”

    Mental health was assessed through questionnaires. (Banellis et al., Nat. Mental Health, 2025)

    The researchers were able to obtain full brain scan data (across 209 brain regions), full stomach scan data, and mental health questionnaires for 199 participants, and this information was then statistically analyzed to look for links.

    Stronger syncing or coupling between brain waves and stomach waves was associated with a higher chance of mental health issues such as anxiety, depression, and stress. Weaker coupling meant a higher chance of better mental health and well-being.

    The data isn’t enough to show that stomach activity is directly triggering mental illness or vice versa, and we don’t know yet why these connections exist. However, it’s a relationship that we may be able to make use of, with further research.

    It builds on what we already know about the enteric nervous system in the gut, connected to the brain via the vagus nerve. Past research has linked this ‘second brain’ to conditions such as autism and neurodegenerative diseases.

    “This part of the gut has been largely ignored,” says neuroscientist Leah Banellis from Aarhus University. “Most research focuses on the microbiome and lower digestive system. Our results suggest stomach rhythms are also deeply tied to emotional well-being.”

    It can be tricky to accurately diagnose mental health problems, with different conditions often overlapping, problems being overlooked or misdiagnosed, and people being reluctant or unable to identify what the issues are. Having other markers for a more precise diagnosis would be very useful.

    Further down the line it might even be possible to adjust feedback from the stomach – the gastric rhythm – to alleviate the symptoms of mental health issues, but that’s a long way off. For now, the researchers want to gather more data on bigger and more diverse groups to see if these patterns can be replicated.

    “We know certain medications and even the foods we eat can influence gastric rhythms,” says Allen. “One day, this research might help us tailor treatments based on how a patient’s body and brain interact – not just what they report feeling.”

    The research has been published in Nature Mental Health.

    Continue Reading

  • Rawshani A, Rawshani A, Gudbjörnsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;377:300–1.

    PubMed 

    Google Scholar 

  • Htay T, Soe K, Lopez-Perez A, Doan AH, Romagosa MA, Aung K. Mortality and cardiovascular disease in type 1 and type 2 diabetes. Curr Cardiol Rep. 2019;21:45.

    PubMed 

    Google Scholar 

  • Das SR, Everett BM, Birtcher KK, Brown JM, Cefalu WT, Januzzi JL Jr, Kalyani RR, Kosiborod M, Magwire ML, Morris PB, Sperling LS. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2018;72:3200–23.

    PubMed 

    Google Scholar 

  • Zhao LM, Zhan ZL, Qiu M. Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. Ther Adv Endocrinol Metab. 2021;23(12):20420188211044944.

    Google Scholar 

  • Kansara A, Mubeen F, Shakil J. SGLT2 inhibitors in patients with chronic kidney disease and heart disease: a literature review. Methodist Debakey Cardiovasc J. 2022;18(4):62–72.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, Lam CSP, Lopes RD, McMurray JJV, Pratley RE, Rosenstock J, Gerstein HC. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62.

    CAS 
    PubMed 

    Google Scholar 

  • Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, Christodorescu RM, Crawford C, Di Angelantonio E, Eliasson B, Espinola-Klein C, Fauchier L, Halle M, Herrington WG, Kautzky-Willer A, Lambrinou E, Lesiak M, Lettino M, McGuire DK, Mullens W, Rocca B, Sattar N, ESC Scientific Document Group. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043–140.

    CAS 
    PubMed 

    Google Scholar 

  • Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227–337.

    PubMed 

    Google Scholar 

  • Hao R, Myroniuk T, McGuckin T, Manca D, Campbell-Scherer D, Lau D, Yeung RO. Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care. 2022;23:124.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Scheen AJ. Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile. Expert Opin Drug Saf. 2024;23:797–810.

    CAS 
    PubMed 

    Google Scholar 

  • Bolden DM, Richardson V, Salahuddin T, Henderson K, Hess PL, Raghavan S, Saxon DR, Ho PM, Waldo SW, Schwartz GG. Evidence-based SGLT2 inhibitor and GLP-1 receptor agonist use by race in the VA healthcare system. Am J Prev Cardiol. 2025;22:100966.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, Ghuman R, Cuthbertson DJ, Lip GYH, Alam U. All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes. Diabetes Obes Metab. 2023;25:2897–909.

    CAS 
    PubMed 

    Google Scholar 

  • Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

    CAS 
    PubMed 

    Google Scholar 

  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    CAS 
    PubMed 

    Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–22.

  • Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T, SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

    CAS 
    PubMed 

    Google Scholar 

  • Chaiyakunapruk N, Tan X, Liang Y, Guevarra M, Xie L, Cheng AYY. Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes. Cardiovasc Diabetol. 2025;24:177.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Liu T, Fan Z, Li Y, Xiao B, He C. Combination treatment of SGLT2i and GLP-1RA associated with improved cardiovascular outcomes in type 2 diabetes patients with acute coronary syndrome: a propensity score-matched cohort study. Int J Cardiol. 2025;431:133229.

    PubMed 

    Google Scholar 

  • Marfella R, Prattichizzo F, Sardu C, Rambaldi PF, Fumagalli C, Marfella LV, La Grotta R, Frigé C, Pellegrini V, D’Andrea D, Cesaro A, Calabrò P, Pizzi C, Antonicelli R, Ceriello A, Mauro C, Paolisso G. GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23:10.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

Continue Reading

  • Nocturnal hypoxemic burden is associated with worsening prognosis of chronic kidney disease in patients with type 2 diabetes | Cardiovascular Diabetology

    Nocturnal hypoxemic burden is associated with worsening prognosis of chronic kidney disease in patients with type 2 diabetes | Cardiovascular Diabetology

  • Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402:203–34.

    Google Scholar 

  • Romagnani P, Agarwal R, Chan JCN, Levin A, Kalyesubula R, Karam S, et al. Chronic kidney disease. Nat Rev Dis Prim. 2025;11:8.

    PubMed 

    Google Scholar 

  • Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117–314.

    Google Scholar 

  • Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet. 2018;392:2052–90.

    PubMed 
    PubMed Central 

    Google Scholar 

  • KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;2022(102):S1–127.

    Google Scholar 

  • Wan EYF, Chin WY, Yu EYT, Wong ICK, Chan EWY, Li SX, et al. The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study. Diabetes Care. 2020;43:1750–8.

    PubMed 

    Google Scholar 

  • Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330:1266–77.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Kious KW, Savage KA, Twohey SCE, Highum AF, Philipose A, Díaz HS, et al. Chronic intermittent hypoxia promotes glomerular hyperfiltration and potentiates hypoxia-evoked decreases in renal perfusion and PO2. Front Physiol. 2023;14:1235289.

    PubMed 
    PubMed Central 

    Google Scholar 

  • O`Neill J, Jasionek G, Drummond SE, Brett O, Lucking EF, Abdulla MA, O’Halloran KD. Renal cortical oxygen tension is decreased following exposure to long-term but not short-term intermittent hypoxia in the rat. Am J Physiol Renal Physiol. 2019;316:F635–45.

    CAS 
    PubMed 

    Google Scholar 

  • Lee Y-C, Hung S-Y, Wang H-K, Lin C-W, Wang H-H, Chen S-W, et al. Sleep apnea and the risk of chronic kidney disease: a nationwide population-based cohort study. Sleep. 2015;38:213–21.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Choi HS, Kim HY, Han K-D, Jung J-H, Kim CS, Bae EH, et al. Obstructive sleep apnea as a risk factor for incident end stage renal disease: a nationwide population-based cohort study from Korea. Clin Exp Nephrol. 2019;23:1391–7.

    CAS 
    PubMed 

    Google Scholar 

  • Sakaguchi Y, Hatta T, Hayashi T, Shoji T, Suzuki A, Tomida K, et al. Association of nocturnal hypoxemia with progression of CKD. Clin J Am Soc Nephrol. 2013;8:1502–7.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Ahmed SB, Ronksley PE, Hemmelgarn BR, Tsai WH, Manns BJ, Tonelli M, et al. Nocturnal hypoxia and loss of kidney function. PLoS ONE. 2011;6: e19029.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Dörhöfer L, Lammert A, Krane V, Gorski M, Banas B, Wanner C, et al. Study design of DIACORE (DIAbetes COhoRtE)—A cohort study of patients with diabetes mellitus type 2. BMC Med Genet. 2013;14:25.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Lampert T, Kroll L, Müters S, Stolzenberg H. Messung des sozioökonomischen Status in der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1) [Measurement of socioeconomic status in the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56:631–6.

    CAS 
    PubMed 

    Google Scholar 

  • Erman MK, Stewart D, Einhorn D, Gordon N, Casal E. Validation of the ApneaLink for the screening of sleep apnea: a novel and simple single-channel recording device. J Clin Sleep Med. 2007;3:387–92.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Stadler S, Zimmermann T, Franke F, Rheinberger M, Heid IM, Böger CA, Arzt M. Association of sleep-disordered breathing with diabetes-associated kidney disease. Ann Med. 2017;49:487–95.

    PubMed 

    Google Scholar 

  • Linz D, Malfertheiner MV, Werner N, Lerzer C, Gfüllner F, Linz B, et al. Nocturnal hypoxemic burden during positive airway pressure treatment across different central sleep apnea etiologies. Sleep Med. 2021;79:62–70.

    PubMed 

    Google Scholar 

  • Baumert M, Immanuel SA, Stone KL, Litwack Harrison S, Redline S, Mariani S, et al. Composition of nocturnal hypoxaemic burden and its prognostic value for cardiovascular mortality in older community-dwelling men. Eur Heart J. 2020;41:533–41.

    PubMed 

    Google Scholar 

  • Stone KL, Blackwell TL, Ancoli-Israel S, Barrett-Connor E, Bauer DC, Cauley JA, et al. Sleep disordered breathing and risk of stroke in older community-dwelling men. Sleep. 2016;39:531–40.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM Manual for the Scoring of Sleep and Associated Events. Deliberations of the Sleep Apnea Definitions Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med. 2012;8:597–619.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Driendl S, Baumert M, Arzt M, Stark KJ, Pec J, Sinha F, et al. Nocturnal hypoxemic burden is associated with incident major adverse cardiovascular events in patients with type 2 diabetes. Eur J Prev Cardiol. 2025.

  • Driendl S, Stadler S, Arzt M, Zeman F, Heid IM, Baumert M. Nocturnal hypoxemic burden and micro- and macrovascular disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2024;23:195.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Leong WB, Nolen M, Thomas GN, Adab P, Banerjee D, Taheri S. The impact of hypoxemia on nephropathy in extremely obese patients with type 2 diabetes mellitus. J Clin Sleep Med. 2014;10:773–8.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Leong WB, Jadhakhan F, Taheri S, Thomas GN, Adab P. The association between obstructive sleep apnea on diabetic kidney disease: a systematic review and meta-analysis. Sleep. 2016;39:301–8.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Hansrivijit P, Puthenpura MM, Ghahramani N, Thongprayoon C, Cheungpasitporn W. Bidirectional association between chronic kidney disease and sleep apnea: a systematic review and meta-analysis. Int Urol Nephrol. 2021;53:1209–22.

    PubMed 

    Google Scholar 

  • Hwu D-W, Lin K-D, Lin K-C, Lee Y-J, Chang Y-H. The association of obstructive sleep apnea and renal outcomes-a systematic review and meta-analysis. BMC Nephrol. 2017;18:313.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang B, Li Z-L, Zhang Y-L, Wen Y, Gao Y-M, Liu B-C. Hypoxia and chronic kidney disease. EBioMedicine. 2022;77: 103942.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Friederich-Persson M, Thörn E, Hansell P, Nangaku M, Levin M, Palm F. Kidney hypoxia, attributable to increased oxygen consumption, induces nephropathy independently of hyperglycemia and oxidative stress. Hypertension. 2013;62:914–9.

    CAS 
    PubMed 

    Google Scholar 

  • Zalucky AA, Nicholl DDM, Hanly PJ, Poulin MJ, Turin TC, Walji S, et al. Nocturnal hypoxemia severity and renin-angiotensin system activity in obstructive sleep apnea. Am J Respir Crit Care Med. 2015;192:873–80.

    CAS 
    PubMed 

    Google Scholar 

  • Piani F, Melena I, Tommerdahl KL, Nokoff N, Nelson RG, Pavkov ME, et al. Sex-related differences in diabetic kidney disease: a review on the mechanisms and potential therapeutic implications. J Diabetes Complic. 2021;35: 107841.

    CAS 

    Google Scholar 

  • Steiger S, Li L, Bruchfeld A, Stevens KI, Moran SM, Floege J, et al. Sex dimorphism in kidney health and disease: mechanistic insights and clinical implication. Kidney Int. 2025;107:51–67.

    CAS 
    PubMed 

    Google Scholar 

  • Shepard BD. Sex differences in diabetes and kidney disease: mechanisms and consequences. Am J Physiol Renal Physiol. 2019;317:F456–62.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Shen Y, Cai R, Sun J, Dong X, Huang R, Tian S, Wang S. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine. 2017;55:66–76.

    CAS 
    PubMed 

    Google Scholar 

  • Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–27.

    CAS 
    PubMed 

    Google Scholar 

  • Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–29.

    CAS 
    PubMed 

    Google Scholar 

  • Continue Reading

  • UK confirms H5N1 bird flu outbreak in southwestern England

    UK confirms H5N1 bird flu outbreak in southwestern England

    (Reuters) -The highly pathogenic avian influenza H5N1 virus was confirmed in poultry at a premises in southwestern England, the UK government said on Sunday.

    A 3 km (about 2 miles) protection zone and 10 km surveillance zone have been declared around the premises near Exminster in Devon, the government said, adding that “all poultry on the premises will be humanely culled.”

    (Reporting by Yazhini MV in BengaluruEditing by Ros Russell)

    Continue Reading

  • Mental time travel: People with ‘hyperthymesia’ remember too much

    Mental time travel: People with ‘hyperthymesia’ remember too much

    A recent case study describes a teenager who can summon personal memories with unusual speed, detail, and control – a very rare condition known as hyperthymesia. She can also use the same mental machinery to imagine future events with striking richness.

    Scientists call this autobiographical memory, the long term store of events from our own lives that includes feelings, places, and people.


    Cognitive scientists also speak of autonoetic consciousness, the reflective awareness that lets us mentally re-experience a past moment and place ourselves in a future one.

    Hyperthymesia – autobiographical memory

    The new paper is led by Valentina La Corte at Paris Cité University and the Paris Brain Institute (PBI). The phenomenon itself is rare, and a comprehensive review notes that the literature is still small and methods vary across studies.

    “In these individuals, known as hyperthymesics, memories are carefully indexed by date. Some will be able to describe in detail what they did [on a specific date], and experience again the emotions and sensations of that day,” explained La Corte.

    The case centers on TL (initials that do not correspond to her real name were given to preserve her anonymity), a 17 year old who does not just recall, she organizes.

    She reports fine grained control over access to memories that many others with hyperthymesia do not describe.

    How she organizes memories

    TL distinguishes a factual store she calls black memory from the personal trove that matters to her sense of self.

    She sorts that personal trove in an internal archive she calls the white room, where memories are arranged in binders by theme and date.

    She places hard experiences in containers to keep their emotional impact manageable, like a chest holding the death of a grandparent.

    She also created adjacent rooms for anger, problems, and even a military room that appeared when her father left for service.

    This mental layout seen in hyperthymesia cases is unusual because it blends chronology, emotion regulation, and self narrative in one controllable space.

    It reflects an effort to keep intrusive details in check without losing access to information that still matters.

    Testing hyperthymesia

    The team used established tools that probe memory for life events and the feeling of mentally traveling through time.

    One of them, TEMPau, measures the sense of reliving across a person’s lifespan and separates richly lived episodes from facts.

    They also used the Temporal Extended Autobiographical Memory task (TEEAM) to extend the timeline and gauge how easily she can move across past and future.

    Across tasks, TL produced unusually vivid, detailed reports and could shift perspective between first person and observer viewpoints.

    The study also considered accuracy. People with very strong autobiographical memory remain vulnerable to distortions, and prior research shows that even highly superior autobiographical memory participants can form false memories under standard laboratory tests.

    Why hyperthymesia matters

    This case is not only about the past. Evidence shows that remembering and imagining recruit overlapping cognitive and neural systems, a point advanced by influential research.

    When TL constructs rich scenes about tomorrow, she appears to harness the same machinery that helps her rebuild yesterday.

    That overlap matters for everyday life. The ability to plan with concrete, sensory details is linked to better goal setting, clearer time estimates, and a stronger sense of identity.

    It also offers a window into clinical puzzles. If future thinking and remembering share processes, then changes that blunt rich recall may also weaken the ability to imagine next week in detail.

    Across published work, highly superior autobiographical memory often involves fast, date anchored retrieval and abundant sensory detail.

    A systematic review reports patterns of overactivation in autobiographical memory networks, including visual regions, during recall.

    At the same time, structural brain differences are not consistent across cases. Functional connectivity differences sometimes appear, but anatomy alone does not explain the skill.

    Human costs and benefits

    Many reported cases carry emotional downsides because painful memories can flood awareness. TL’s approach is notable because she uses mental tools to tag and quarantine difficult episodes without erasing them.

    That strategy raises practical questions for therapy and education. If people can be taught to structure personal memories with themes and timelines, perhaps they can gain clarity without amplifying distress.

    It also raises ethical questions. A mind that retrieves with this intensity may feel compelled to revisit moments that others allow to fade, which can complicate decision making and mood.

    The field still needs better tools to check the accuracy of distant life events against real dates and sources. It also needs longitudinal data to see whether abilities like TL’s change with age or with life transitions.

    “It is difficult to generalize findings about hyperthymesia, since they rely on only a few cases,” concluded La Corte. The next wave of studies will need larger samples, tighter validation, and standardized tasks across labs.

    The study is published in Neurocase.

    —–

    Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

    Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

    —–

    Continue Reading

  • Leeds woman with terminal cancer makes Ironman comeback

    Leeds woman with terminal cancer makes Ironman comeback

    Grace Wood and Jonathan ReedBBC News, Yorkshire

    BBC A woman smiles at the camera. She is wearing a blue cap and a blue T shirt and big black-rimmed glassesBBC

    Hannah Corne was forced to pull out halfway through the race in July, but completed it a month later

    A woman with terminal cancer has completed an Ironman challenge a month after she was forced to stop the race due to intense pain.

    Hannah Corne, from Leeds, was taking part in Ironman Leeds on 27 July when she was forced to pull out halfway through the cycling section of the race.

    This weekend, she completed the cycle ride and marathon at Roundhay Park, watched by friends and family.

    She said: “It feels amazing. Ironman was one of the best days of my life. It was such an incredible thing to be a part of and to be able to finish it today is the icing on the cake.”

    Ms Corne completed the remainder of the 56-mile (90km) cycle race on Saturday and then ran a marathon (26 miles or 42km) on Sunday.

    Fifteen months ago she was diagnosed with stage four ocular melanoma, a rare cancer that spread to her liver and was told she had 12 months to live.

    About 30 people stand around in running gear. In the middle a child holds a homemade banner that says Go Hannah

    Hannah Corne was joined in the challenge by her friends and family

    She said as long as her body continued to allow her she would carry on setting herself physical challenges.

    “It’s to show that even when you’ve got a devastating diagnosis like stage four cancer you can still live well and enjoy life.”

    She thanked her friends and family for joining her on the route.

    She added: “It’s overwhelming. I didn’t think so many people would be out, but they have all come out in force with snacks and great times and chat. It’s brilliant.”

    Continue Reading

  • Beta-Blockers Linked to Worse Outcomes in Women Following a Heart Attack

    Beta-Blockers Linked to Worse Outcomes in Women Following a Heart Attack

    Valentín Fuster, MD, PhD
    Credit: Mount Sinai

    Research from the European Society of Cardiology (ESC) Congress 2025 provides important new insight into the sex-specific outcomes following a heart attack, including the effect of beta-blockers.

    The data, which were an analysis of the REBOOT clinical trial, suggest women experience worse outcomes than their male counterparts following a myocardial infarction (MI) and those treated with beta-blockers post-event had a greater risk of mortality, reinfarction, and hospitalization for heart failure compared to women not receiving the class of medication.1,2

    “We have been investigating sex-differences in cardiovascular disease for a long time. We already knew that cardiovascular disease presentation is different in women and men, and this study significantly adds to this knowledge by showing that response to medications is not necessarily equal in women and men,” said study investigator Valentín Fuster, MD, PhD, president of the Mount Sinai Foster Heart Hospital and at the Nacional de Investigaciones Cardiovasculares Carlos III (CNIC).2 “This study should spark the much-needed sex-specific approach for cardiovascular disease”.

    Initiated by investigators at the CNIC as a randomized, open-blinded endpoint trial, the REBOOT trial was launched in 2018 to explore the effect of beta-blocker therapy, a guideline-directed medical therapy in patients with heart failure with reduced ejection fraction, in patients with a MI and who had a left ventricular ejection fraction (LVEF) of at least 40% or more. Presented at ESC Congress 2025 and simultaneously published in the New England Journal of Medicine, the overall trial concluded there was no evidence of an effect on all-cause death, reinfarction or heart failure admission, with events occurring among 316 patients in the beta-blocker group and in 307 patients in the no beta-blocker group (hazard ratio (HR), 1.04; 95% confidence interval [CI], 0.89 to 1.22; P = .63).3

    In addition to primary results, investigators presented a post hoc analysis at ESC Congress 2025 examining sex-specific differences in the trial.1

    Of the 8438 patients included in the intention-to-treat population, 1627 were women. Results suggested women in the trial were older, had more comorbidities, and received fewer guideline-based therapies than men.1

    During a median follow-up of 3.7 years, women had overall higher rates of the primary composite outcome than men, with an incidence rate in women of 30.4 per 1000 patient-years in the beta-blocker group and 21.0 per 1000 patient-years in the no beta-blocker group (HR, 1.45; 95% CI, 1.04 to 2.03). In contrast, no significant differences were observed among men included in the trial (HR, 0.94; 95% CI, 0.79 to 1.13; P for interaction = .026).1

    Further analysis demonstrated the excess risk observed in women was primarily driven by increased mortality and was most evident among those with preserved LVEF (P for interaction = .030) and those receiving higher beta-blocker doses (P for interaction = .045).1

    “Our findings suggest that a one-size-fits-all approach may not be appropriate and that sex-specific considerations are crucial for cardiovascular interventions prescriptions,” said study investigator Xavier Rosselló, MD, PhD, a scientist at CNIC and a cardiologist at University Hospital Son Espases in Mallorca.2

    References:
    1. Rosello X, Dominguez-Rodriguez A, Latini R. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. European Heart Journal. Published online August 30, 2025. doi: 10.1093/eurheartj/ehaf673
    2. Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.). New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers. EurekAlert! Published August 30, 2025. Accessed August 31, 2025. https://www.eurekalert.org/news-releases/1096049
    3. Ibanez B, Latini R, Rossello X, et al. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction. New England Journal of Medicine. Published online August 30, 2025. doi: 10.1056/nejmoa2504735

    Continue Reading

  • Billions Of Dollars Are Flowing Into “Dementia Tech”

    Billions Of Dollars Are Flowing Into “Dementia Tech”

    An NIH study published earlier this year cited a jarring fact: researchers estimate that there is nearly a 42% lifetime risk of dementia for those over the age of 55. In the context of this alarming figure, it is important to note that dementia is a broader umbrella term for memory loss and degradation of thinking in various forms that impact activities of daily living (ADLs). Per the Alzheimer’s association, forms of dementia present as part of a larger spectrum, including:

    • Alzheimer’s disease
    • Vascular dementia
    • Lewy body dementia
    • Frontotemporal dementia
    • And many other, mixed and hybrid variations

    However, regardless of the specific category or disease name, it’s a condition which can significantly impact quality of life.

    Fortunately, billions of dollars are being poured into “dementia tech”: technology enabled services that can significantly aid the diagnostic, therapeutic and lifestyle aspects of these conditions.

    Take for example Isaac Health, which provides an “in-home” memory clinic service for brain health and memory issues. The company provides a platform to enable assessment, treatment and most importantly, ongoing support and management for patients and caregivers that are experiencing memory conditions. Isaac Health just announced $10.5 in Series A funding, supported by big investor names such as Flare Capital, Black Opal Ventures and Meridian Street Capital.

    Another prominent startup in this space that has gained significant attention is Rippl Care, which provides on-demand care services for those with dementia. Last year, the company acquired Kinto, a small startup dedicated to providing education to caregivers of patients with dementia. Overall, Rippl reports that its services have actually led to a 30% reduction in emergency department visits for seniors with dementia.

    The wider technology ecosystem is slowly evolving in a way that better serves this healthcare spectrum. The entire world of wearable devices, such as smart watches, glasses, rings etc., serve dementia patients well, as they are able to send reminders, track location and provide accessibility during emergencies. For example, the fall detection feature in the Apple Watch provides alerts in case the user experiences a fall and will automatically call emergency services if they are immobile for a minute or more. This is a huge boon for individuals that may experience memory loss as to where they are at any given time and do not have access to nearby emergency services otherwise.

    There’s even an entire application ecosystem for patients with memory loss and dementia to help maintain and gain memory functions. For example, one of the most popular apps is Lumosity, which provides memory exercises and brain training programs.

    Why is all of this so important?

    Because dementia is a widespread condition that impacts millions of people. The World Health Organization states that in 2021 alone, nearly 57 million people were afflicted with some form of dementia. With increasing disease burden and an aging population across the globe, these numbers will only continue to increase.

    Thus, innovation and investment in this arena are positive steps in the right direction. With enough research and support, perhaps there will be a future in which this disease can be prevented or cured, altogether.

    Continue Reading